The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases

Keller, Martin B.; Trivedi, Madhukar H.; Thase, Michael E.; Shelton, Richard C.; Kornstein, Susan G.; Nemeroff, Charles B.; Friedman, Edward S.; Gelenberg, Alan J.; Kocsis, James H.; Dünner, David L.; Dunlop, Boadie W.; Hirschfeld, Robert M. A.; Rothschild, Anthony J.; Ferguson, James M.; Schatzberg, Alan F.; Zajecka, John; Pedersen, Ronald; Yan, Bing Chun; Ahmed, Saeeduddin; Schmidt, Michael D.; Ninan, Philip T.

doi:10.1016/j.biopsych.2007.04.040

Cited by 39 publications

(49 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PREVENT study was a double-blind, randomized, multiphase study, conducted in accordance with the Declaration of Helsinki, that included adult patients with a history of recurrent MDD defined as two or more episodes of depression in the previous 5 years, and at least three lifetime episodes of depression [16]. Patients were required to meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for MDD with a 17-item Hamilton Rating Scale for Depression (HAM-D 17 ) score of 20 or more at screening and at least 18 at the baseline visit, and were excluded if they had a history of treatment-resistant depression, DSM-IV bipolar or anxiety disorders, psychosis or any significant medical disorder.…”

Section: Methodsmentioning

confidence: 99%

“…Satisfactory response was defined as a total score of 12 or less and at least a 50% decrease from baseline; a score of 7 or less was needed to achieve remission [16]. Differences in treatment response were calculated using a Cochran-Mantel-Haenszel χ-square test during the acute and continuation phases.…”

Section: Methodsmentioning

confidence: 99%

“…The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study evaluated the efficacy of venlafaxine extended release (ER) compared with placebo for long-term prevention of recurrence in patients with MDD who responded to acute and continuation therapy [16][17][18]. The multiphase study design allowed for evaluation of the benefits of continuing therapy at various points in time.…”

Section: Prevent Studymentioning

confidence: 99%

“…Similarly, comparable efficacy was observed during the continuation phase. Response rates were 90 and 92%, remission rates were 72 and 69%, and sustained remission rates (i.e., meeting remission criteria for two consecutive visits) were 52 and 58% with venlafaxine ER and fluoxetine, respectively [16]. These relatively high response and remission rates are likely due to the lack of a placebo comparison group.…”

mentioning

confidence: 92%

See 3 more Smart Citations

Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study

Kornstein¹

2008

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

The need for maintenance therapy in patients with major depressive disorder (MDD) is underscored by the high likelihood of recurrence after short-term treatment. Current recommendations include treatment to remission and long-term treatment to prevent relapse and recurrence. This article will summarize the design and results of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study, which have been published elsewhere. PREVENT evaluated venlafaxine extended release (ER) versus placebo in two 1-year maintenance phases for prevention of recurrence in patients with MDD who responded to acute and continuation therapy. Venlafaxine ER was effective in preventing long-term recurrence when compared with placebo, with a significant reduction in likelihood of recurrence and significantly longer time to recurrence after both 1 and 2 years of maintenance therapy. Recurrence rates in the first and second maintenance periods for patients receiving placebo were similar (42 vs 45%), but recurrence rates for patients receiving venlafaxine ER decreased dramatically (23 vs 8%). The PREVENT study adds to current understanding regarding the benefits of long-term antidepressant therapy in preventing recurrence.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Prevent Studymentioning

confidence: 99%

mentioning

confidence: 92%

See 2 more Smart Citations

Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study

Kornstein¹

2008

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis of those who continued on drug, Williams, Simpson, Simpson, and Nahas (2009) report that 23% will relapse by one year, 34% relapse by two years, and 45% relapse by three years. Keller et al (2007) looked at relapse rates for individuals who had experienced at least two episodes of depression prior to entry into their study. They followed those who responded during the initial ten weeks of treatment for six months.…”

Section: Antidepressantsmentioning

confidence: 99%